In addition, DUXAP10 overexpression was positively correlated with the adverse clinicopathological features and aggressive outcomes of several cancer types, including tumor size, TNM staging, histological grading, lymph node metastasis, and survival rates. Here, DUXAP10 is linked to metastatic malignant neoplasm in the lymph nodes.